SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023
Share
SCI Pharmtech, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 313.12 million compared to TWD 181.36 million a year ago. Revenue was TWD 313.12 million compared to TWD 181.36 million a year ago. Net income was TWD 199.52 million compared to TWD 140.34 million a year ago. Basic earnings per share from continuing operations was TWD 1.86 compared to TWD 1.31 a year ago. Diluted earnings per share from continuing operations was TWD 1.86 compared to TWD 1.31 a year ago.
For the six months, sales was TWD 654.89 million compared to TWD 369.38 million a year ago. Revenue was TWD 654.89 million compared to TWD 369.38 million a year ago. Net income was TWD 262.96 million compared to TWD 181.52 million a year ago. Basic earnings per share from continuing operations was TWD 2.45 compared to TWD 1.69 a year ago. Diluted earnings per share from continuing operations was TWD 2.45 compared to TWD 1.69 a year ago.
SCI Pharmtech, Inc. is a Taiwan-based company principally engaged in the processing, manufacture and sales of Active Pharmaceutical Ingredients (APIs). The Company's main products include APIs, API intermediates and special and precision chemicals. The Company distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
SCI PHARMTECH, INC. 
